Acute otitis media in an era of increasing antimicrobial resistance and universal administration of pneumococcal conjugate vaccine

Pediatric Infectious Disease Journal

Volumn 21, Issue 6, 2002, Pages 599-604

  Pelton, Stephen I ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute otitis media; Antibiotic resistance; Management

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFIXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; COTRIMOXAZOLE; MACROLIDE; PNEUMOCOCCUS VACCINE; ANTIINFECTIVE AGENT; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; VACCINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIUM ISOLATE; CHILD; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDICATION; EPIDEMIOLOGICAL DATA; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; OTITIS MEDIA; PRIORITY JOURNAL; RISK ASSESSMENT; SEROTYPE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; VACCINATION; ACUTE DISEASE; BACTERIAL INFECTION; CLASSIFICATION; DRUG EFFECT; DRUG RESISTANCE; HAEMOPHILUS INFLUENZAE; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MORAXELLA CATARRHALIS; REVIEW; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE;

ACUTE DISEASE; ANTIBIOTICS; BACTERIAL INFECTIONS; CHILD; DRUG RESISTANCE; HAEMOPHILUS INFLUENZAE; HUMAN; INFANT; MENINGOCOCCAL VACCINES; MORAXELLA (BRANHAMELLA) CATARRHALIS; OTITIS MEDIA; PNEUMOCOCCAL VACCINES; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE; ANTI-BACTERIAL AGENTS; HUMANS;

EID: 0036285349     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200206000-00036     Document Type: Conference Paper

References (38)

1. Randomised study of myringotomy, amoxycillin/clauvulante, or both for acute otitis media in infants
2. Amoxicillin or myringotomy or both for acute otitis media: Results of a randomized clinical trial
3. Primary care: Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media
4. National differences in incidence of acute mastoiditis: Relationship to prescribing patterns of antibiotics for acute otitis media?
5. Restricted use of antibiotic prophylaxis for recurrent acute otitis media in ther era of penicillin non-susceptible Streptococcus pneumoniae
6. Microbiology of otitis media in the Paris, France, area from 1987 to 1997
7. Acute otitis media caused by Streptococcus pneumoniae in children's hospitals between 1994 and 1997: The US Pediatric Multicenter Surveillance Group
8. The "otitis-prone" condition
9. Epidemiology of otitis media during the first seven years of life in children in greater Boston: A prospective, cohort study
10. Host factors and early therapeutic response in acute otitis media
11. Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life
12. Multidrug resistant pneumococci in the US.: 1997-2001 TRUST surveillance
13. Macrolide resistance in Finnish Streptococci: A continuing struggle with better weapons
14. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37 000 infants and children: Impact on pneumonia, otitis media and update on invasive disease: Results of The Northern California Kaiser Permanente Efficacy Trial
15. Efficacy of a pneumococcal conjugate vaccine against otitis media
16. Effect of a 7-valent pneumococcal conjugate vaccine (PncOMPC) on acute otitis media (AOM) due to vaccine serotypes after boosting with conjugate or polysaccharide vaccines
17. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine
18. Effect of pneumococcal conjugate vaccine (PCV-7) on nasopharyngeal carriage among Native American vaccines and their household siblings
19. Immunization of toddlers attending day care centers (DCCs) with a 9-valent conjugate pneumococcal vaccine (PncCRM9) reduces transmission of Streptococcus pneumoniae (Pnc) and antibiotic resistant S. pneumoniae (R-Pnc) to their young siblings (YS)
20. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome
21. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
22. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
23. Clinical significance of resistant organisms in otitis media
24. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media
25. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media infants and young children
26. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US Surveillance study
27. Middle ear fluid concentrations of amoxicillin after large doses in children with acute otitis media
28. Middle ear effusion amoxicillin concentrations in acute otitis media
29. Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media
30. Acute otitis media: Management and surveillance in an era of pneumococcal resistance: A report from the Drug-resistant Streptococcus Therapeutic Working Group
31. Clinical relapse of otitis media (CR-AOM) within 1 month after completion of treatment (Tx): Bacteriologic correlates
32. Antibiotic treatment in acute otitis media promotes superinfection with resistant Streptococcus pneumoniae carried before initiation of treatment
33. Bacteriologic efficacy of a three-day intramuscular ceftriaxone regimen in nonresponsive acute otitis media
34. Increasing antibiotic resistance among otitis media pathogens and their susceptibility to oral agents based on pharmacodynamic parameters
35. Experimental otitis media (AOM) due to non-typable Haemophilus influenzae: Comparison of high and low dose azithromycin with placebo
36. Prevalence of single mutations in topcisomerase IV and DNA gyrase among US levofloxacin susceptible clinical isolates of Streptococcus pneumoniae
37. Bacteriologic efficacy of gatifloxacin (GATI) in the treatment of recurrent/nonresponsive acute otitis media (RNR-AOM)
38. Population pharmacokinetic analysis of gatifloxacin in pediatric patients